Reviewed by Peptide Treatments Medical Advisory Board (Medical Advisory Board)

MK-677: Regulatory Status

Current legal and regulatory status for MK-677 across jurisdictions. This page reflects the most recent verified information and is updated as regulatory actions occur.

Back to MK-677 overview

United States

Research Only

Compounding status: available through research chemical suppliers. WADA: prohibited (S2 — peptide hormones, growth factors, and related substances). not approved in any jurisdiction. Widely available as a "research chemical." China banned MK-677 in 2020 as part of SARMs/peptide enforcement. FDA has issued warning letters to companies selling MK-677 as a dietary supplement.

Last verified:

What This Means

Reclassification is not the same as FDA approval.

Even if MK-677 moves to Category 1, it remains an off-label therapeutic that requires physician supervision. Category 1 means it can be compounded under section 503A — it does not confer approved-drug status.

MK-677 Overview

Uses, benefits, evidence, and monitoring.

Contraindications

Safety profile and drug interactions.

Evidence Summary

Clinical trial data and evidence tiers.